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Summary
Background Our aim was to assess the long-term risks of death, disability, and rebleeding in patients randomly 
assigned to clipping or endovascular coiling after rupture of an intracranial aneurysm in the follow-up of the 
International Subarachnoid Aneurysm Trial (ISAT).
Methods 2143 patients with ruptured intracranial aneurysms were enrolled between 1994 and 2002 at 
43 neurosurgical centres and randomly assigned to clipping or coiling. Clinical outcomes at 1 year have been 
previously reported. All UK and some non-UK centres continued long-term follow-up of 2004 patients enrolled in 
the original cohort. Annual follow-up has been done for a minimum of 6 years and a maximum of 14 years (mean 
follow-up 9 years). All deaths and rebleeding events were recorded. Analysis of rebleeding was by allocation and by 
treatment received. ISAT is registered, number ISRCTN49866681.
Findings 24 rebleeds had occurred more than 1 year after treatment. Of these, 13 were from the treated aneurysm (ten 
in the coiling group and three in the clipping group; log rank p=0·06 by intention-to-treat analysis). There were 
8447 person-years of follow-up in the coiling group and 8177 person-years of follow-up in the clipping group. 
Four rebleeds occurred from a pre-existing aneurysm and six from new aneurysms. At 5 years, 11% (112 of 1046) of 
the patients in the endovascular group and 14% (144 of 1041) of the patients in the neurosurgical group had died 
(log-rank p=0·03). The risk of death at 5 years was signiﬁ cantly lower in the coiling group than in the clipping group 
(relative risk 0·77, 95% CI 0·61–0·98; p=0·03), but the proportion of survivors at 5 years who were independent did 
not diﬀ er between the two groups: endovascular 83% (626 of 755) and neurosurgical 82% (584 of 713). The standardised 
mortality rate, conditional on survival at 1 year, was increased for patients treated for ruptured aneurysms compared 
with the general population (1·57, 95% CI 1·32–1·82; p<0·0001).
Interpretation There was an increased risk of recurrent bleeding from a coiled aneurysm compared with a clipped 
aneurysm, but the risks were small. The risk of death at 5 years was signiﬁ cantly lower in the coiled group than it 
was in the clipped group. The standardised mortality rate for patients treated for ruptured aneurysms was increased 
compared with the general population.
Funding UK Medical Research Council.
Introduction
Endovascular coiling for the treatment of intracranial 
aneurysms was ﬁ rst introduced into clinical use in 
1990. A prospective randomised trial, the International 
Subarachnoid Aneurysm Trial (ISAT), which was 
supported by the Medical Research Council (MRC), was 
commenced as a pilot study in 1994 and ceased 
recruitment in 2002. 2143 patients with a recently 
ruptured intracranial aneurysm were enrolled in 
43 centres and were randomly assigned to neurosurgical 
clipping or endovascular coiling. The trial protocol, 
methods, and results at 1 year have been published.1–3 
The results demonstrated that coiling was associated 
with a reduction in the risk of death and dependency at 
1 year, which was the primary outcome: 250 (24%) of 
1063 patients randomly assigned to coiling were dead 
or dependent compared with 326 (31%) of 
1055 patients randomly assigned to clipping, a relative 
risk reduction in death or dependence at 1 year of 
23·9% (95% CI 12·4–33·9) and an absolute risk 
reduction of 7·4% (3·6–11·2; p=0·0001). 
Since the introduction of coiling of cerebral aneurysms, 
there have been concerns about the durability of coil 
treatment and its ability to prevent subsequent rebleeding 
of the treated aneurysm. This is particularly important 
because many individuals with ruptured intracranial 
aneurysms are young; the mean age at entry into the trial 
was 52 years. Thus, patients who survive in good clinical 
condition following treatment have a potentially long life 
expectancy. The angiographic occlusion rates of coiling 
are worse than the rates after surgical clipping,4–6 and a 
higher proportion of patients required retreatment of a 
previously coiled aneurysm.4 The limited long-term 
follow-up data after coiling was acknowledged in both 
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our earlier papers and has been emphasised throughout 
the published works.7,8
In addition, evidence is emerging that patients who 
have an initial subarachnoid haemorrhage (SAH) from 
an aneurysm are at greater risk of the formation of a new 
aneurysm and a further SAH compared with the general 
population;9,10 furthermore, they might have a higher 
overall standardised risk of death compared with the age-
matched and sex-matched population.11 
One of the original objectives of ISAT, which was set 
out in the protocol, was to continue long-term follow-up 
of the randomised patients in a systematic manner in an 
attempt to answer these questions. We continue to follow 
up all UK patients, and some Scandinavian and Canadian 
centres follow up patients in their respective countries. 
This has provided a unique opportunity to observe, 
prospectively, in a well-deﬁ ned population who have had 
clipping or coiling, the risk of further subarachnoid 
haemorrhage and other related complications, including 
long-term risk of death, after treatment of a ruptured 
cerebral aneurysm.
Methods
Patients
The trial methodology was described in detail in the 
protocol and has been published elsewhere with the 
inclusion criteria, ethics approval, and consent criteria.1,2 
Table 1 shows the baseline characteristics. 
Procedures
The centres that are undertaking long-term follow-up 
enrolled 2004 patients of the original cohort of 2143. The 
patients receive annual postal questionnaires concerning 
their dependency, quality of life (EUROQOL [EQ5D]), and 
whether they have had any further hospital admissions or 
further treatment related to their SAH or aneurysm. All 
UK patients are ﬂ agged with the Oﬃ  ce for National 
Statistics (ONS), and the Oxford Neurovascular and 
Neuroradiology Research Unit (ONNRU) automatically 
receives notiﬁ cation of the death of all patients in the study 
who have died in the UK. Suspected instances of rebleeding 
are either brought to the attention of investigators by the 
centre, self-reported by the patient or their family, or 
identiﬁ ed when notiﬁ ed by ONS to ONNRU; the same is 
true of any further hospital admissions. The data in respect 
of any rebleeds are collected, including the date, any 
operative reports, post-mortem reports, and imaging data. 
These were reviewed by an experienced neurosurgeon 
(RSCK, NR) and neuroradiologist (AJM). All centres 
followed-up patients annually for 5 years. All UK and eight 
non-UK centres continue to follow-up patients annually.
Statistical analysis
Survival analyses were done for time to rebleeding and 
time to death, measured from the time of the initial SAH. 
For the analysis of time to rebleeding, observations were 
censored when a patient was lost to follow-up or had 
died. For the analysis of time to death, observations were 
censored when a patient was lost to follow-up. Data were 
retrieved for up to 5 years for all UK and non-UK deaths 
and for more than 5 years in all UK centres and those 
non-UK centres that continued follow-up. Data for the 
survival and rebleed analyses were extracted on 
Aug 31, 2008. Kaplan–Meier curves were calculated for 
each treatment group, and the groups were compared with 
the log-rank test. We calculated Kaplan–Meier curves for 
the rebleeding events on the basis of allocated group and 
by actual treatment received. The analyses were performed 
with Stata, version 10 (StatCorp LP, TX, USA). 
To calculate the standardised mortality ratios (SMRs) 
all patients’ deaths were included from a date 1 year from 
the date of their SAH until the end of 2007. Standard 
death rates for England and Wales were used, which 
covered 5-year age bands from 15 until 25 years, 10-year 
age bands until 85 years of age, and one age band for 
over 85 years, for all years from 1998 until 2007. The 
number of patients alive on the ﬁ rst day of each year, at 
least 1 year from the date of their SAH was ascertained, 
and the number of deaths during the year was counted. 
165 dead at Aug 31, 2008
        126 in UK
          39 non-UK
834 alive at September, 2008
          790 in UK
            44 non-UK
   13 lost to follow-up†
         5 in UK
         8 non-UK
     8 refused further follow-up‡
         7 in UK
         1 non-UK
813 eligible for long-term 
         follow-up
          778 in UK
             35 non-UK
1070 randomly assigned
           to neurosurgery
           834 in UK
           236 non-UK
2143 enrolled
  74 at non-UK centres with 
        no follow-up at 5 years*
  65 at non-UK centres with 
       no follow-up at 5 years*
194 dead at Aug 31, 2008
        166 in UK
           28 non-UK
811 alive at September, 2008
        668 in UK
         143 non-UK
 28 lost to follow-up†
       20 in UK
         8 non-UK
 14 refused further follow-up‡
      13 in UK
         1 non-UK
769 eligible for long-term
         follow-up
         635 in UK
         134 non-UK
1073 randomly assigned to 
           endovascular treatment
           916 in UK
            157 non-UK
Figure 1: Study proﬁ le
*Some non-UK centres no longer follow-up patients. †Lost patients had moved abroad (from country of 
randomisation) or had had no contact with study centre or primary-care physician since the ﬁ rst or second year of 
study. ‡Patient has withdrawn or they no longer wish to participate.
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The age of each patient was assessed as though at the 
midpoint of each year. The expected number of deaths 
was calculated for each year and summed over all years.
ISAT is registered, number ISRCTN49866681.
Role of the funding source
The sponsor had no role in the study design, data 
collection, data analysis, data interpretation, or the writing 
of the report. The principal investigators (RSCK and AJM) 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Figure 1 shows the study proﬁ le. Complete loss to follow-
up was 2·7% at a mean of 9 years. As of August, 2008, 
there were 1307 survivors in the UK and 275 survivors in 
non-UK centres who continued follow-up; some non-UK 
centres ceased follow-up after 5 years (late non-UK 
follow-up is unfunded). We report these data to a 
minimum of 6 years and a maximum of 14 years after 
enrolment in the trial.
Table 2 shows the conﬁ rmed rebleeding (recurrent 
SAH) events. 24 rebleeds have been conﬁ rmed in 
24 patients. In 13 patients, the rebleeding was from the 
treated aneurysm or in the same location as the previously 
treated aneurysm, but in ten patients the bleeding 
occurred from either a new aneurysm or a pre-existing 
aneurysm that had not previously ruptured. In one 
patient the source of the haemorrhage was unknown. In 
four patients the bleeding occurred from another 
aneurysm that was seen at the original presentation, and 
in six patients the bleeding was conﬁ rmed as arising 
from a new (de novo) aneurysm, which had not been 
present on the angiogram at the time of the original 
presentation. Figure 2 shows the Kaplan–Meier curve of 
time to rebleed from the target aneurysm by the treatment 
received.
In the endovascular cohort, there were ten episodes of 
rebleeding from the treated aneurysm after 1 year in 
8447 person-years of follow-up. In these ten patients the 
rebleeding arose from the aneurysm that had been 
treated after SAH. Of these ten patients, three died within 
30 days of the second bleed, two were disabled after 
rebleed and retreatment (mRS scores of 4 or 5 at follow-
up), and four patients were retreated and were 
independent at follow-up, although one of these died 
2 years later of cancer. One patient rebled 2 days after a 
second aneurysm coiling for a neck remnant but did not 
require any further treatment and was independent at 
follow-up.
In three patients, rebleeding was shown to occur from 
another known aneurysm, and in another three patients, 
rebleeding occurred from a new aneurysm that was not 
present on the original angiogram. In one patient, it was 
impossible to establish the source of the recurrent SAH. 
In the neurosurgical cohort, three patients had a 
further subarachnoid haemorrhage from the treated 
aneurysm after 1 year in 8177 person-years of follow-up; 
all three patients died within 30 days of the rebleed. 
One of these patients, who had an anterior 
communicating artery aneurysm, had declined surgery 
after randomisation and underwent coiling of the 
aneurysm. The aneurysm was incompletely occluded at 
follow-up angiography, but the patient declined further 
treatment, and rebled in year 4. The other two patients 
underwent surgical clipping of the ruptured aneurysm 
(a middle cerebral and an anterior communicating 
artery aneurysm, respectively). Occlusion of the 
aneurysms was judged complete at surgery in both, but 
no early or late postoperative angiography was done. 
The patients rebled and died at 6·5 years and 7 years, 
respectively. One patient bled from another known 
Endovascular 
(n=1073)
Neurosurgery 
(n=1070)
Men 400 (37%) 398 (37%)
Age (years) 52 (44–60 [18–87]) 52 (43–60 [18–84])
WFNS grade
1 674 (63%) 661 (62%)
2 269 (25%) 280 (26%)
3 66 (6%) 68 (6%)
4 38 (4%) 36 (3%)
5 11 (1%) 9 (1%)
6 (not assessable) 15 (1%) 16 (1%)
Maximum size of the lumen of the target aneurysm
≤5 mm 553 (52%) 572 (53%)
6–10 mm 437 (41%) 426 (40%)
≥11 mm 83 (8%) 72 (7%)
Number of aneurysms
1 836 (78%) 850 (79%)
2 173 (16%) 170 (16%)
3 44 (4%) 35 (3%)
≥4 20 (2%) 15 (1%)
Time between SAH and 
randomisation (days)
2 (1–4 [0–26]) 2 (1–5 [0–28])
Data are number (%) or median (IQR [range]). WFNS= World Federation of 
Neurosurgical Societies. SAH=subarachnoid haemorrhage.
Table 1: Baseline characteristics
Rebleeding 
from target 
aneurysm*
Rebleeding from aneurysm 
that was known at 
baseline†
De novo 
aneurysm‡
Unknown 
aneurysm
Total
Endovascular 
(8447 person-years)
10 (3) 3 (2) 3 (1) 1 (1) 17 (7)
Neurosurgery 
(8177 person-years)
3 (3)§ 1 (1) 3 (2) 0 7 (6)
Total 13 (6) 4 (3) 6 (3) 1 (1) 24 (13)
Numbers in parenthesis are deaths within 30 days of bleeding.*The target aneurysm is identiﬁ ed at the time of 
enrolment in the trial. †Other known aneurysms that were seen on the ﬁ rst angiogram but are not thought to have 
ruptured. ‡De novo aneurysms that were not seen on the ﬁ rst angiogram. §One patient crossed over to coiling. 
SAH=subarachnoid haemorrhage. 
Table 2: Rates of recurrent SAH after more than 1 year by treatment allocation
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aneurysm, and three patients bled from a new aneurysm 
that was not present at the time of the original 
angiogram. The time to recurrent SAH from the 
treatment of the aneurysm in the endovascular group 
was between 2 and 5 years. In the surgical group, the 
time to recurrent SAH was between 4 and 7 years 
(ﬁ gure 2). There was a non-signiﬁ cant increased risk of 
rebleeding from the treated aneurysm in the endovascular 
cohort (log rank p=0·06) by intention-to-treat analysis 
and a signiﬁ cant diﬀ erence when analysis was by actual 
treatment received (log rank p=0·02). There was no 
diﬀ erence between the groups in mortality rates as a 
result of rebleeding. The time to recurrent haemorrhage 
from pre-existing aneurysms was between 2 and 4 years, 
and that from new aneurysms was between 4 and 
9 years.
Endovascular
Neurosurgery
0
0·02
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0·08
0·10
0 2 4 6 8 10 12 14
(1) (3) (7) (0) (0) (0) (0)
(0) (0) (0) (2) (0) (0) (0)
1099 1022 968 920 585 268 57 0
1044 925 891 853 555 239 52 0
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Number at risk (target rebleed)
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Figure 2: Kaplan–Meier graph of cumulative risk of rebleed from the treated aneurysm after more than 1 year by treatment allocation
Patients followed up for a minimum of 6 years and a maximum of 14 years. SAH=subarachnoid haemorrhage. 
0
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Figure 3: Kaplan–Meier graph of cumulative mortality rate
Patients followed up for a minimum of 6 years and a maximum of 14 years. SAH=subarachnoid haemorrhage.
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The number of deaths reported to the end of August, 
2008, was 359. The predominant causes of death after 
1 year in both groups were cancer or cardiovascular 
disease and these were listed in our previous report.2 
Case-fatality rates at 1 year were 8·0% (95% CI 6·4–9·8) 
and 9·9% (8·2–11·0) among patients allocated to 
endovascular treatment and neurosurgery, respectively. 
At 5 years, 112 of 1046 (11%) and 144 of 1041 (14%) patients 
were dead among those allocated to the endovascular 
and neurosurgical treatment groups, respectively (odds 
ratio [OR] 0·75, 95% CI 0·58–0·97; p=0·03). Figure 3 
shows the Kaplan–Meier curves for cumulative mortality 
and numbers at risk at seven time points. Table 3 shows 
the SMRs of the UK cohort, conditional on 1 year survival 
after the SAH and based on deaths to the end of 2007. 
There have been a further 91 deaths since the preparation 
of the data in 2004: 35 due to cancer, 21 due to 
cardiovascular disease, eight due to respiratory disease, 
ﬁ ve due to ischaemic stroke, and two probable suicides. 
Six deaths were due to recurrent SAH: ﬁ ve from another 
aneurysm and one from the treated aneurysm (a clipped 
patient). 12 deaths were due to various causes that were 
unrelated to the SAH; the causes of two deaths are 
unknown.
The primary outcome of the trial was death or 
dependency. At 5 years, mRS scores were available for 
867 of 1073 patients in the endovascular group and 857 of 
1070 patients in the neurosurgical group. 41 patients (2%) 
were completely lost to follow-up. The mRS score for 
dependency at the 5-year follow-up was missing for 
178 patients in the endovascular group and 184 patients 
in the neurosurgical group, but their vital status was 
known. The number of missing mRS scores did not 
diﬀ er between the groups; in most patients values were 
available for earlier or later years. The proportion of 
patients with an mRS of 2 or less (ie, independent) 
conditional on survival at 5 years, was 626 of 755 (83%) in 
the endovascular group and 584 of 713 (82%) in the 
neurosurgical group; mRS scores were also available at 
other time points before and after 5 years, but a 
longitudinal analysis of these data is beyond the scope of 
this paper. Table 4 shows the mRS scores available at 
5 years in both groups.
Discussion
There is continuing concern, particularly in the 
neurosurgical community, that the initial observed 
clinical beneﬁ t of coiling compared with clipping could 
be lost over time if subsequent rebleeding rates are high. 
The data we now report are reassuring. Although, on the 
basis on these data, the annual risk of the treated 
aneurysm rebleeding is higher in the patients treated by 
coiling than in the patients treated by clipping, the risk 
remains low and is at a similar level to the risk of further 
SAH from another source, either a pre-existing 
aneurysm or a newly formed aneurysm. Until recently, 
neurosurgeons had assumed that the risk of a recurrent 
SAH after clipping of an aneurysm was close to zero. 
Recent data from Wermer and coauthors9 on the late 
risk of haemorrhage in a large cohort of patients who 
previously had their aneurysms clipped showed a 
signiﬁ cantly increased risk of recurrent SAH compared 
with the general population (22 times [95% CI 12–38] 
compared with age-matched and sex-matched 
population).9 Wermer and coauthors also found the 
prevalence of aneurysms to be 17% on follow-up CT 
angiography.12 The data we report here appear to support 
this ﬁ nding and suggest that the previous assumptions 
that the risk of recurrent SAH was similar to that in the 
general population were incorrect. The baseline 
characteristics of the ISAT cohort were similar in terms 
of sex, age at the time of the haemorrhage, and 
proportion of patients with several aneurysms. 
Of the patients who have a SAH from a ruptured 
aneurysm, about 20% have more than one aneurysm at 
Endovascular 
(n=1046*; n=867†)
Neurosurgery 
(n=1041*; n=857†)
mRS score
0 (no symptoms) 264 198
1 (minor symptoms) 217 211
2 (some restriction in lifestyle) 145 175
3 (substantial restriction in lifestyle) 83 93
4 (partly dependent) 24 18
5 (fully dependent) 22 18
6 (dead) 112 144
0–2 inclusive 626 584
3–6 inclusive 241 273
Probability of independence conditional on survival 
at 5 years
626 of 755 (83%) 584 of 713 (82%)
Probability of death 112 of 1046 (11%) 144 of 1041 (14%)
Relative risk of non-independence conditional on 
survival at 5 years
0·99, 0·94–1·03, p=0·61
Relative risk of death at 5 years 0·77, 0·61–0·98, p=0·03
Probability of survival and independence at 5 years 74% 71% 
Data are number; number (%); relative risk, 95% CI, p value; or percentage. mRS=modiﬁ ed Rankin scale. 
*Ascertainment for death was almost complete but dependency status was missing (n=27 for endovascular; n=29 for 
neurosurgery). †Incomplete ascertainment of mRS at 5 years (n=206 missing for endovascular; n=213 missing for 
neurosurgery). Reasons for missing mRS score: centre did not follow up patients (n=56); mRS not available, data 
temporarily or permanently missing, or no dependency outcome value given at year 5 (n=418).
Table 4: Clinical outcomes at 5 years
Observed 
deaths
Expected 
deaths
SMR p
All 144 92 1·57 (1·32–1·82) <0·0001
Female 90 55 1·65 (1·32–1·98) <0·0001
Male 54 37 1·46 (1·09–1·83) 0·02
Endovascular 63 46 1·37 (1·04–1·70) 0·03
Neurosurgery 81 46 1·77 (1·00–2·14) <0·0001
Data are number or SMR (95% CI). Ratios were calculated for the UK cohort 
conditional on survival at 1 year. SMR=standardised mortality ratio. 
Table 3: Standardised mortality ratios calculated for UK cohort, 
conditional on survival at 1 year
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the time of presentation and have a continuing risk of 
developing new aneurysms. Smoking and female 
gender are known risk factors for new aneurysm 
formation and SAH; unfortunately, smoking history 
was not collected during the trial. The timing of late 
recurrent haemorrhage is noteworthy; all rebleeding 
events from the coiled aneurysms have so far occurred 
within 5 years of the initial event, whereas the late 
recurrent haemorrhages that have occurred after 5 years 
have been from another aneurysm or, in one patient, a 
clipped aneurysm. This raises the possibility that the 
risk of a recurrent haemorrhage from a treated 
aneurysm might not be constant over time; however, a 
substantially longer observation period would be 
needed to conﬁ rm if this is the case.
Our ﬁ ndings conﬁ rm those of Wermer and coauthors 
that patients who have had treatment for a ruptured 
aneurysm have a small but deﬁ nitely increased risk of 
recurrent SAH compared with the general population. 
The late all-cause mortality risk is also increased 
compared with the general population, and the SMR in 
the surviving UK population is signiﬁ cantly increased 
(p<0·0001). This raises the important issue of how best 
to follow up patients with coiled or clipped aneurysms. 
In recent years, there has been a rapid shift from the use 
of invasive angiography in the follow-up of patients with 
coiled aneurysms to the use of non-invasive MRI 
techniques, such as magnetic resonance angiography 
(MRA), contrast-enhanced MRA, and CT angiography 
(CTA) in patients with clipped aneurysms. These imaging 
methods are much more acceptable to patients and 
involve no angiographic stroke risk; however, any 
follow-up screening for the recurrence of new aneurysms 
has substantial health-care costs and the potential for 
substantial psychological morbidity and anxiety.13 What is 
of considerable importance is strong advice on smoking 
cessation and the proper management of hypertension 
and other cardiovascular risk factors. 
The question asked in the neurosurgical community 
about coiling has always been: will the early proven 
beneﬁ t of coiling be lost in the long term? This question 
was highlighted and modelled in a recent paper and 
associated commentary.14,15 This paper has given rise to 
controversy, particularly with respect to the management 
of young patients with ruptured aneurysms (younger 
than 40 years, who were only a small subgroup in the 
trial).14
The level of risk we now report and the absence of an 
increase in risk of death between the patients treated 
with coiling and those treated with clipping over what is 
now a mean of 9 years follow-up would appear not to 
change the message of our original paper; namely, that 
for patients with suitable aneurysms, coiling is more 
likely than clipping to result in improved clinical 
outcomes at 1 year, and these data suggest that although 
the early clinical beneﬁ ts are reduced over time, they are 
not lost over the subsequent 4 years. We have previously 
reported4 that patients undergoing coiling were more 
likely to require delayed aneurysm retreatment. Late 
retreatment (more than 3 months after ﬁ rst treatment) 
was done in 9% of patients who had coiling, a hazard 
ratio of 6·9 (95% CI 3·4–14·1) compared with clipping. 
However, there was no change in mRS score at follow-up 
after further treatment; thus, the further treatment after 
initial coiling had no eﬀ ect on the 5-year outcomes.4 At 
5 years, there is a signiﬁ cantly reduced risk of death in 
the endovascular group compared with the neurosurgical 
group. For those patients who are alive at 5 years, there is 
no signiﬁ cant diﬀ erence in the probability of being 
independent, which appears to indicate the continuing 
improvement in the functional outcome of less severely 
disabled patients in the surgical group between year 2 
and year 5. One explanation for this might be an increased 
case-fatality rate among the more severely dependent 
patients who had neurosurgery.
The inferences from all these reports are the same: the 
extrapolation of the results of any clinical trial to 
individual patients must be done after weighing all the 
factors of an individual’s circumstances, the health-care 
environment, the equipment available, the availability of 
relevant neurosurgical and endovascular skills, the 
anatomy and location of the aneurysm and the relative 
diﬃ  culties for the endovascular or surgical approach in 
the speciﬁ c case, and the age and clinical state of the 
patient. These are all factors that could aﬀ ect the advice 
that might be provided to patients and their relatives. 
This emphasises the need for patients with such a 
complicated care pathway to be managed at centres 
where both treatment options are available.
When ISAT started recruiting patients in 1994, there 
were understandable questions about the change in 
technology that might occur in the interim and thus the 
relevance to clinical practice when such an inevitably 
long trial is completed. Patients were enrolled in ISAT 
during an early phase in the use of detachable coils; the 
ﬁ rst patient was enrolled only 2·5 years after the device 
was approved for clinical use in Europe and before the 
US Food and Drug Administration (FDA) gave approval. 
At that time, the range and performance of detachable 
coils and their associated catheters were limited. 
Considerable advances have taken place in the technical 
performance of coils and catheters, and in operator 
experience, technical expertise, and digital radiographic 
imaging systems, particularly three-dimensional 
angiography, which have all substantially improved since 
the trial was started. These developments might have 
reduced the risks of coiling; certainly, it seems unlikely 
that the current procedural or rebleeding risks are greater 
than those observed during the trial and the follow-up. 
The results of three other randomised studies that have 
recently completed recruitment—the Barrow Randomised 
Aneurysm Trial (BRAT) of coiling compared with clipping 
in ruptured aneurysm at a large US neurosurgical centre; 
the HydroCoil Endovascular Aneurysm Occlusion and 
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Packing Study (HELPS) to compare hydrogel-coated coils 
with bare platinum coils;16 and the Cerecyte Coil Trial to 
compare polymer-loaded coils with standard platinum 
coils—will provide invaluable data on the current early 
clinical outcomes for patients undergoing coiling of a 
ruptured aneurysm. Further observation of the ISAT 
cohort will continue until at least 2013.
The ISAT follow-up for a mean of 9 years (range 
6–14 years) demonstrates that the risk of rebleeding from 
a treated aneurysm is low. There were more rebleeds 
from the treated aneurysm in the coiling group than in 
the clipping group, but there was no diﬀ erence between 
the groups in the number of deaths due to rebleeding. 
The risk of death at 5 years was signiﬁ cantly lower in the 
coiled group than it was in the clipping group. The 
probability of independent survival for those patients 
alive at 5 years is the same in the two groups. The SMR, 
conditional on survival at 1 year, is increased in patients 
treated for ruptured aneurysms compared with the 
general population.
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